Inventiva: financing agreement for NATiV3 study

(CercleFinance.com) - Inventiva announces that it has secured immediate financing of €94.
1 million, as part of a multi-tranche financing package of up to €348 million, subject to the fulfillment of certain conditions.

The proceeds of the financing will be used primarily to carry out the phase 3 clinical trial, NATiV3, evaluating lanifibranor in over 1,100 randomized patients in non-cirrhotic MASH, with the last randomized patient expected in the first half of 2025.

As part of the transaction, and subject to ratification by the AGM to be held no later than December 16, Inventiva has appointed Mark Pruzanski as Chairman of the Board and Srinivas Akkaraju as a Director.

Up to four additional directors may be appointed by the four main investors, two of whom, qualified as independent, will replace the existing directors (excluding Frédéric Cren, Mark Pruzanski and Srinivas Akkaraju).

Copyright (c) 2024 CercleFinance.com. All rights reserved.